Zanubrutinib demonstrates superior progression-free survival vs ibrutinib for relapsed/refractory CLL/SLL: ALPINE final analysis

被引：0

作者：

Munir, Talha ^{[1
]}

Brown, Jennifer R. ^{[2
]}

Eichhorst, Barbara ^{[3
]}

Hillmen, Peter ^{[4
]}

Lamanna, Nicole ^{[5
]}

O'Brien, Susan M. ^{[6
]}

Tam, Constantine S. ^{[7
,8
]}

Qiu, Lugui ^{[9
,10
]}

Kazmierczak, Maciej ^{[11
]}

Jurczak, Wojciech ^{[12
]}

Zhou, Keshu ^{[13
]}

Simkovic, Martin ^{[14
,15
]}

Mayer, Jiri ^{[16
,17
]}

Gillespie-Twardy, Amanda

Ferrajoli, Alessandra ^{[18
,19
]}

Ganly, Peter S. ^{[20
]}

Weinkove, Robert ^{[21
,22
]}

Grosicki, Sebastian ^{[23
]}

Mital, Andrzej ^{[24
]}

Robak, Tadeusz ^{[25
]}

Osterborg, Anders ^{[26
,27
]}

Yimer, Habte A. ^{[28
]}

Salmi, Tommi ^{[29
,30
]}

Wang, Megan ^{[29
,30
]}

Fu, Lina ^{[29
,30
]}

Li, Jessica ^{[29
,30
]}

Wu, Kenneth ^{[29
,30
]}

Cohen, Aileen ^{[29
,30
]}

Shadman, Mazyar ^{[31
,32
]}

机构：

[1] Leeds Hosp NHS Trust, Leeds, England

[2] Dana Farber Canc Inst, Boston, MA USA

[3] Univ Cologne, Ctr Integrated Oncol Aachen, Bonn, Germany

[4] St James Univ Hosp, Leeds, England

[5] Columbia Univ, Herbert Irving Comprehens Canc Ctr, New York, NY USA

[6] Univ Calif Irvine, Chao Family Comprehens Canc Ctr, Irvine, CA USA

[7] Alfred Hosp, Melbourne, Australia

[8] Monash Univ, Melbourne, Australia

[9] Chinese Acad Med Sci & Peking Union Med Coll, Inst Haematol, Natl Clin Res Ctr Haematol Disorders, State Key Lab Expt Haematol, Tianjin, Peoples R China

[10] Chinese Acad Med Sci & Peking Union Med Coll, Blood Dis Hosp, Tianjin, Peoples R China

[11] Poznan Univ Med Sci, Dept Haematol & Bone Marrow Transplantat, Poznan, Poland

[12] Maria Sklodowska Curie Natl Res Inst Oncol, Krakow, Poland

[13] Zhengzhou Univ, Henan Canc Hosp, Affiliated Canc Hosp, Zhengzhou, Peoples R China

[14] Univ Hosp, Dept Internal Med Haematol 4, Hradec Kralove, Czech Republic

[15] Charles Univ Prague, Fac Med, Prague, Czech Republic

[16] Masaryk Univ, Dept Internal Med Haematol & Oncol, Brno, Czech Republic

[17] Univ Hosp, Brno, Czech Republic

[18] Blue Ridge Canc Care, Roanoke, VA USA

[19] Univ Texas MD Anderson Canc Ctr, Dept Leukaemia, Houston, TX USA

[20] Christchurch Hosp, Dept Haematol, Christchurch, New Zealand

[21] Whatu Ora Hlth New Zealand Capital Coast & Hutt, Rerenga Ora Blood & Canc Ctr, Wellington, New Zealand

[22] Malaghan Inst Med Res, Canc Immunotherapy Programme, Wellington, New Zealand

[23] Med Univ Silesia, Fac Hlth Sci, Dept Haematol & Canc Prevent, Katowice, Poland

[24] Med Univ Gdansk, Dept Haematol & Transplantol, Gdansk, Poland

[25] Med Univ Lodz, Lodz, Poland

[26] Karolinska Inst, Dept Oncol Pathol, Stockholm, Sweden

[27] Karolinska Univ Hosp, Dept Haematol, Stockholm, Sweden

[28] Texas Oncol Tyler US Oncol Res, Tyler, TX USA

[29] BeiGene Beijing Co Ltd, Beijing, Peoples R China

[30] BeiGene Inc, San Mateo, CA USA

[31] Fred Hutchinson Canc Ctr, Seattle, WA USA

[32] Univ Washington, Dept Med, Seattle, WA USA

来源：

BRITISH JOURNAL OF HAEMATOLOGY | 2023年 / 201卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

BSH23-OR17

引用

页码：14 / 15

页数：2

共 50 条

[1] Zanubrutinib Demonstrates Superior Progression-Free Survival (PFS) Compared with Ibrutinib for Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (R/R CLL/SLL): Results from Final Analysis of ALPINE Randomized Phase 3 Study
Brown, Jennifer R.
Eichhorst, Barbara
Hillmen, Peter
Lamanna, Nicole
O'Brien, Susan M.
Tam, Constantine S.
Qiu, Lugui
Kazmierczak, Maciej
Jurczak, Wojciech
Zhou, Keshu
Simkovic, Martin
Mayer, Jiri
Gillespie-Twardy, Amanda L.
Ferrajoli, Alessandra
Ganly, Peter S.
Weinkove, Robert
Grosicki, Sebastian
Mital, Andrzej
Robak, Tadeusz
Osterborg, Anders
Yimer, Habte A.
Salmi, Tommi
Wang, Megan
Fu, Lina
Li, Jessica
Wu, Kenneth
Cohen, Aileen
Shadman, Mazyar
BLOOD, 2022, 140 : 19 - 23
[2] Zanubrutinib Demonstrates Superior Progression- Free Survival (PFS) Compared with Ibrutinib for Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (R/R CLL/SLL): Results from Final Analysis of the ALPINE Randomized Phase 3 Study
CS, Tam
Brown, J. R.
Kahl, B. S.
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2023, 21 (02) : 12 - 13
[3] Extended Follow-up of ALPINE Randomized Phase 3 Study Confirms Sustained Superior Progression-Free Survival of Zanubrutinib Versus Ibrutinib for Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (R/R CLL/SLL)
不详
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2024, 22 (01)
[4] Extended Follow-up of ALPINE Randomized Phase 3 Study Confirms Sustained Superior Progression-Free Survival of Zanubrutinib Versus Ibrutinib for Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (R/R CLL/SLL)
Brown, Jennifer R.
Eichhorst, Barbara F.
Lamanna, Nicole
O'Brien, Susan M.
Tam, Constantine S.
Qiu, Luqui
Kazmierczak, Maciej
Jurczak, Wojciech
Zhou, Keshu
Simkovic, Martin
Mayer, Jiri
Gillespie-Twardy, Amanda L.
Ferrajoli, Alessandra
Ganly, Peter S.
Weinkove, Robert
Grosicki, Sebastian
Mital, Andrzej
Robak, Tadeusz
Osterborg, Anders
Yimer, Habte A.
Wang, Megan
Salmi, Tommi
Wang, Liping
Li, Jessica
Wu, Kenneth
Cohen, Aileen Cleary
Shadman, Mazyar
BLOOD, 2023, 142
[5] Toxicity, Progression-Free Survival, and Quality of Life of Patients Treated with Zanubrutinib Versus Ibrutinib: A Q-TWiST Analysis from the ALPINE Study in Relapsed or Refractory Chronic Lymphocytic Leukemia
Levy, Vincent
Srivastava, Tushar
Yang, Keri
Purkayastha, Palash
Gautam, Raju
Wang, Kaijun
Mohseninejad, Leyla
BLOOD, 2023, 142
[6] First Interim Analysis Of ALPINE Study: Results Of A Phase 3 Randomized Study Of Zanubrutinib Vs Ibrutinib In Patients With Relapsed / Refractory Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma (CLL / SLL)
Hillmen, Peter
Eichhorst, Barbara
Brown, Jennifer R.
Lamanna, Nicole
O'brien, Susan
Tam, Constantine S.
Qiu, Lugui
Kazmierczak, Maciej
Zhou, Keshu
Simkovic, Martin
Mayer, Jiri
Gillespie-Twardy, Amanda
Shadman, Mazyar
Ferrajoli, Alessandra
Ganly, Peter S.
Weinkove, Robert
Salmi, Tommi
Ji, Meng
Yecies, Jessica
Wu, Kenneth
Novotny, William
Huang, Jane
Jurczak, Wojciech
ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 3) : 143 - 144
[7] Depth of Response and Progression-Free Survival in CLL Patients on Ibrutinib
不详
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2018, 16 (07) : 8 - 9
[8] Alpine: Phase 3 Trial of Zanubrutinib (BGB-3111) Vs Ibrutinib in Patients with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
Hillmen, Peter
Brown, Jennifer R.
Byrd, John C.
Eichhorst, Barbara F.
Lamanna, Nicole
O'Brien, Susan M.
Qiu, Lugui
Salmi, Tommi
Hilger, James
Huang, Jane
Tam, Constantine S.
BLOOD, 2019, 134
[9] Ibrutinib for relapsed/refractory CLL: A UK and Ireland survival analysis
Follows, G.
BRITISH JOURNAL OF HAEMATOLOGY, 2016, 173 : 96 - 96
[10] First Interim Analysis of ALPINE Study: Results of a Phase 3 Randomized Study of Zanubrutinib vs Ibrutinib in Patients With Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
Brown, Jennifer R.
Hillmen, Peter
Eichhorst, Barbara
Lamanna, Nicole
O'Brien, Susan
Tam, Constantine S.
Qiu, Lugui
Kazmierczak, Maciej
Zhou, Keshu
Simkovic, Martin
Mayer, Jiri
Gillespie-Twardy, Amanda
Shadman, Mazyar
Ferrajoli, Alessandra
Ganly, Peter S.
Weinkove, Robert
Salmi, Tommi
Wu, Kenneth
Novotny, William
Jurczak, Wojciech
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S266 - S266

← 1 2 3 4 5 →